Spinal muscular atrophy market to reach $3bn across 7MM by 2033

The spinal muscular atrophy (SMA) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is poised to grow at a compound annual growth rate (CAGR) of 1.2% from $2.7bn in 2023 to $3bn in 2033, according to GlobalData’s recently published report, Spinal Muscular Atrophy: Opportunity Assessment and Forecast. This modest growth will be driven by an increase in the population of patients eligible for gene transfer therapy and the anticipated introduction of three late-stage pipeline products during the forecast period.